NY-AB-INBEV
30.5.2024 07:01:28 CEST | Business Wire | Press release
Today, Danone has joined AB InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD), The Coca-Cola Company, Colgate-Palmolive Company, and Unilever as the fifth partner in the 100+ Accelerator, the groundbreaking program dedicated to pioneering sustainable innovation across global supply chains.
Launched in 2018 by AB InBev, the 100+ Accelerator has rapidly become a cornerstone initiative for catalyzing environmental stewardship and sustainable business practices through global collaboration and groundbreaking solutions in critical areas such as water stewardship, circular economy, sustainable agriculture, and climate action. In 2021, the 100+ Accelerator welcomed its first three partners to expand this unique approach to innovation and to further establish the value proposition of the program’s brand and mission. To date, it has accelerated 148 companies in 38 countries.
“Sustainability is core to our business strategy and fulfills our purpose of dreaming big to create a future with more cheers,” said Ingrid De Ryck, Chief Sustainability Officer of AB InBev. “In the 5 years since its launch, the 100+ Accelerator has helped us identify and scale solutions to business challenges, advance our 2025 sustainability goals and improve resilience across supply chains. We welcome Danone as a strategic partner in the 100+ Accelerator and are excited to continue developing the program’s impact through industry collaboration.”
“Our combined global reach will undoubtedly propel the 100+ Accelerator to new heights, driving broader adoption of sustainable innovations that will benefit our planet, our communities and our future.” Vikram Agarwal, Chief Operations Officer, Danone, also expressed his enthusiasm for the partnership: "This collaboration with 100+ Accelerator is yet another milestone in Danone's sustainability journey and is a direct result of our Partner For Growth program. It shows our commitment to working with all partners across our ecosystem to leverage our respective strengths to create shared value. With 100+ Accelerator, start-ups will be able to harness our internal resources to scale-up innovation that will deliver tangible environmental benefits across the value chain.”
Isabelle Esser, Danone Chief Research, Innovation, Quality and Food Safety Officer added, “We are proud to join the 100+ Accelerator program, which is fully aligned with our ambition to drive sustainable innovation for the future of our planet and our consumers. At Danone, we believe that strong partnerships are essential to help us stay one step ahead of global challenges, while continuing to honor our mission of shaping the food of tomorrow.”
The program's effectiveness is evidenced by its impact:
- Implementation of a range of technologies that help improve water efficiency including nanotechnology, electrochemistry and spectroscopy.
- Enhanced traceability and support systems for smallholder farmers, endeavoring to improve livelihoods and agricultural sustainability across continents.
- Fleet optimization including EV retrofitting, hydrogen co-fueling, aerodynamic solutions and hybrid charging.
- New cooling applications including thermodynamic coatings and magnetic refrigeration.
- Bio-based, compostable packaging alternatives or additives from banana fiber, spent grain, corn husk, bacterial nano-cellulose among others.
Applications for the sixth cohort of the accelerator will open on May 30. Forward-thinking entrepreneurs are invited to apply at www.100accelerator.com.
With the collective capabilities of AB InBev, The Coca-Cola Company, Colgate-Palmolive, Danone, and Unilever, the 100+ Accelerator will continue to scale innovative solutions to create a more sustainable world.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240529855383/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom